dihydroxyacetone
Small moleculeexperimental
Dihydroxyacetone phosphate (DHAP, also glycerone phosphate in older texts) is the anion with the formula HOCH2C(O)CH2OPO32-. This anion is involved in many metabolic pathways, including the Calvin cycle in plants and glycolysis. It is the phosphate ester of dihydroxyacetone. — Wikipedia
Clinical trial activity
6 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1997 (NCT00003143)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CO)CO- Mol. weight
- 90.08 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDihydroxyacetone phosphate ↗
- ChEMBLCHEMBL1229937 ↗
Also known as
- 1,3-dihydroxy-2-propanone monodihydrogen phosphate
- 1,3-dihydroxy-2-propanone monodihydrogen phosphate
- 1,3-dihydroxy-2-propanone phosphate
- 1,3-dihydroxy-2-propanone phosphate
- 1,3-dihydroxyacetone 1-phosphate
- 1,3-dihydroxyacetone 1-phosphate
- 1-hydroxy-3-(phosphonooxy)-2-propanone
- 1-hydroxy-3-(phosphonooxy)-2-propanone
- 1-hydroxy-3-(phosphonooxy)acetone
- 1-hydroxy-3-(phosphonooxy)acetone
- 3-hydroxy-2-oxopropyl phosphate
- 3-hydroxy-2-oxopropyl phosphate
- dhap
- dhap
- dhap
- dihydroxyacetone
- dihydroxyacetone
- dihydroxyacetone
- dihydroxyacetone monophosphate
- dihydroxyacetone monophosphate
- dihydroxyacetone phosphate
- dihydroxyacetone phosphate
- glycerone monophosphate
- glycerone monophosphate
- glycerone phosphate
- glycerone phosphate
- vitadye
- vitadye
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02280993 | Phase 1 | May 1, 2014 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Takeda, University of Amsterdam |
| NCT01453504 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | University of Cologne |
| NCT01626664 | Phase 2 | Jun 1, 2012 | Kyowa Hakko Kirin |
| NCT01453205 | Phase 2 | Feb 1, 2012 | MedImmune |
| NCT00384553 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2004 | University of Magdeburg |
| NCT00003143 | Phase 2 | Nov 1, 1997 | University of California, Los Angeles |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Kyowa Hakko Kirin | For profit | 1 | 1 | 1 | 2012 |
| MedImmune | For profit | 1 | 1 | 1 | 2012 |
| Takeda | For profit | 1 | 0 | 1 | 2014 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 1997 |
| University of Cologne | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Magdeburg | Academic/Hospital | 1 | 1 | 1 | 2004 |
8 organizations
Page 1 / 1